These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Aging, estrogen loss and epoxyeicosatrienoic acids (EETs). Lee AR; Pechenino AS; Dong H; Hammock BD; Knowlton AA PLoS One; 2013; 8(8):e70719. PubMed ID: 23967089 [TBL] [Abstract][Full Text] [Related]
26. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors. Pillarisetti S; Khanna I Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237 [TBL] [Abstract][Full Text] [Related]
27. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Imig JD Adv Pharmacol; 2016; 77():105-41. PubMed ID: 27451096 [TBL] [Abstract][Full Text] [Related]
28. The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Yang T; Peng R; Guo Y; Shen L; Zhao S; Xu D Lipids Health Dis; 2013 Oct; 12():151. PubMed ID: 24148690 [TBL] [Abstract][Full Text] [Related]
29. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Fang X; Hu S; Xu B; Snyder GD; Harmon S; Yao J; Liu Y; Sangras B; Falck JR; Weintraub NL; Spector AA Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H55-63. PubMed ID: 16113065 [TBL] [Abstract][Full Text] [Related]
30. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice. Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266 [TBL] [Abstract][Full Text] [Related]
31. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Oltman CL; Weintraub NL; VanRollins M; Dellsperger KC Circ Res; 1998 Nov; 83(9):932-9. PubMed ID: 9797342 [TBL] [Abstract][Full Text] [Related]
32. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Larsen BT; Gutterman DD; Hatoum OA Eur J Clin Invest; 2006 May; 36(5):293-300. PubMed ID: 16634832 [TBL] [Abstract][Full Text] [Related]
33. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. Behm DJ; Ogbonna A; Wu C; Burns-Kurtis CL; Douglas SA J Pharmacol Exp Ther; 2009 Jan; 328(1):231-9. PubMed ID: 18836067 [TBL] [Abstract][Full Text] [Related]
34. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling. Lai J; Chen C Front Physiol; 2021; 12():642470. PubMed ID: 33716791 [TBL] [Abstract][Full Text] [Related]
35. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314 [TBL] [Abstract][Full Text] [Related]
36. Regulation of forskolin-induced cAMP production by cytochrome P450 epoxygenase metabolites of arachidonic acid in HEK293 cells. Abukhashim M; Wiebe GJ; Seubert JM Cell Biol Toxicol; 2011 Oct; 27(5):321-32. PubMed ID: 21519968 [TBL] [Abstract][Full Text] [Related]
38. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Fleming I Trends Pharmacol Sci; 2007 Sep; 28(9):448-52. PubMed ID: 17764757 [TBL] [Abstract][Full Text] [Related]
39. Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. Alsaad AM; Zordoky BN; Tse MM; El-Kadi AO Drug Metab Rev; 2013 May; 45(2):173-95. PubMed ID: 23600686 [TBL] [Abstract][Full Text] [Related]
40. EET signaling in cancer. Panigrahy D; Greene ER; Pozzi A; Wang DW; Zeldin DC Cancer Metastasis Rev; 2011 Dec; 30(3-4):525-40. PubMed ID: 22009066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]